載入中
NASDAQHealthcareBiotechnology
最新資料
US$746.54
+US$6.97 · +0.94%
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
前收盤價
US$746.54
+US$6.97 · +0.94%
盤中時間採用ET。市場資料可能有所延遲。
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
日內區間
目前US$746.54
52週區間
目前US$746.54
盤中時間採用ET。市場資料可能有所延遲。
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
日內區間
目前US$746.54
52週區間
目前US$746.54
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$849.84
上漲空間 13.84%| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年8月18日 | US$0.94Quarterly | 2026年8月18日 | 2026年8月31日 |
股息 | 2026年5月20日 | US$0.94Quarterly | 2026年5月20日 | 2026年6月4日 |
股息 | 2026年2月20日 | US$0.94Quarterly | 2026年2月20日 | 2026年3月5日 |
股息 | 2025年11月20日 | US$0.88Quarterly | 2025年11月20日 | 2025年12月5日 |
股息 | 2025年8月18日 | US$0.88Quarterly | 2025年8月18日 | 2025年9月3日 |
股息 | 2025年5月20日 | US$0.88Quarterly | 2025年5月20日 | 2025年6月6日 |
除息 2026年8月18日
US$0.94
Quarterly
2026年8月18日登記 · 支付日 2026年8月31日
除息 2026年5月20日
US$0.94
Quarterly
2026年5月20日登記 · 支付日 2026年6月4日
除息 2026年2月20日
US$0.94
Quarterly
2026年2月20日登記 · 支付日 2026年3月5日
除息 2025年11月20日
US$0.88
Quarterly
2025年11月20日登記 · 支付日 2025年12月5日
除息 2025年8月18日
US$0.88
Quarterly
2025年8月18日登記 · 支付日 2025年9月3日
除息 2025年5月20日
US$0.88
Quarterly
2025年5月20日登記 · 支付日 2025年6月6日
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T1398.89億0.11%129.35兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI26.17億0.11%2.3兆 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO21.2億0.12%1.8兆 USD0.03%US$715.59+0.61%
Invesco QQQ Trust, Series 1QQQ15.75億0.31%5060.67億 USD0.18%US$751.27+0.49%
iShares Core S&P 500 ETFIVV9.64億0.11%8964.4億 USD0.03%US$781.97+0.60%
Vanguard Morningstar Mid-Cap ETFVO8.9億0.39%2264億 USD0.03%US$81.14+0.92%
State Street SPDR S&P 500 ETFSPY8.84億0.11%8172億 USD0.09%US$778.57+0.60%
Vanguard Morningstar Value ETFVTV7.87億0.30%2624億 USD0.03%US$220.59+0.44%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOInvesco QQQ Trust, Series 1QQQiShares Core S&P 500 ETFIVVVanguard Morningstar Mid-Cap ETFVOState Street SPDR S&P 500 ETFSPYVanguard Morningstar Value ETFVTVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
